BLOPRESS

Negara: Indonesia

Bahasa: Bahasa Indonesia

Sumber: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency

Bahan aktif:

CANDESARTAN

Tersedia dari:

TAKEDA INDONESIA - Indonesia

INN (Nama Internasional):

CANDESARTAN

Dosis:

8 MG

Bentuk farmasi:

TABLET

Unit dalam paket:

DUS, 4 BLISTER @ 7 TABLET

Diproduksi oleh:

TAKEDA INDONESIA - Indonesia

Tanggal Otorisasi:

2016-07-14

Karakteristik produk

Based on CCDS Candesartan Cilexetil ver. 22.0 dated June 19, 2021.
1
BLOPRESS
® TABLET
8 MG AND 16 MG
CANDESARTAN CILEXETIL
COMPOSITION
Blopress tablets 8 mg are round pale pink tablets with a single score
line on one sides. Each tablet contains 8
mg candesartan cilexetil.
Blopress tablets 16 mg are round pink tablets with no score. Each
tablet contains 16 mg candesartan
cilexetil.
PHARMACOLOGICAL ACTIONS
Angiotensin II is the primary vasoactive hormone of the
renin-angiotensin-aldosterone system and plays a
significant role in the pathophysiology of hypertension, heart failure
and other cardiovascular disorders. It is
also has an important role in the pathogenesis of end organ
hypertrophy and damage.
The major physiological effects of angiotensin II, such as
vasoconstriction, aldosterone stimulation, regulation
of salt and water homeostasis and stimulation of cell growth, are
mediated via the type I (AT
1
) receptor.
Blopress is a prodrug suitable for oral use. It is rapidly converted
to the active drug, candesartan, by ester
hydrolysis during absorption from the gastrointestinal tract. Blopress
is an angiotensin II receptor antagonist,
selective for AT
1
receptor, with tight binding to and slow dissociation from the
receptor. It has no agonist
activity.
Candesartan does not inhibit ACE, which convert angiotensin I to
angiotensin II and degrades bradykinin.
There is no effect on ACE and no potentiation of bradykinin or
substance P. In controlled clinical trials
comparing Blopress with ACE-inhibitor, the incidence of cough was
lower in patients receiving Blopress.
Candesartan does not bind to or block other hormone receptors or ion
channels known to be important in
cardiovascular regulation.
_HYPERTENSION _
In hypertension, Blopress causes a dose–dependent, long lasting
reduction in arterial blood pressure. The
antihypertensive action is due to decreased systemic peripheral
resistance, while heart rate, stroke volume
and cardiac output are not affected. There is no indication of serious
exaggerate first –dos